Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

被引：2
|
作者：
Bernstein, Ezra [1 ]
Luo, Jia [2 ]
Wang, Kaiwen [3 ]
Negrao, Marcelo V. [4 ]
Janne, Pasi A. [2 ]
Sabari, Joshua K. [5 ]
机构：
[1] NYU, Langone Dept Internal Med, 251 East 33rd St, New York, NY 10016 USA
[2] Dana Faber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
D O I：
10.1200/PO.23.00447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Case series demonstrates activity of adagrasib in untreated CNS metastases across multiple scenarios.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer
    Heng, Sarina Z. W.
    Hoo, Regina
    Tan, Daniel S. W.
    CANCER DISCOVERY, 2023, 13 (07) : 1513 - 1515
  • [22] Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review (vol 8, e2300644, 2024)
    Luo, Jia
    JCO PRECISION ONCOLOGY, 2024, 8
  • [23] KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
    Klempner, S. J.
    Weiss, J.
    Pelster, M.
    Spira, A.
    Barve, M.
    Ou, S-H. I.
    Leal, A.
    Bekaii-Saab, T.
    Christensen, J. G.
    Kheoh, T.
    Velastegui, K.
    Torossian, H. Der
    Yaeger, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1391 - S1391
  • [24] Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC)
    Kim, Eejung
    Tong, Xinyuan
    Patel, Ayushi
    Liu, Shengwu
    Dilly, Julien
    Hover, Laura
    Mukhopadhyay, Suman
    Sherman, Fiona
    Christensen, James G.
    Olson, Peter
    Aguirre, Andrew
    Wong, Kwok
    Ji, Hongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naive, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Garassino, M. C.
    Theelen, W. S. M. E.
    Jotte, R.
    Laskin, J.
    De Marinis, F.
    Aguado, C.
    Badin, F. B.
    Chmielewska, I.
    Hochmair, M. J.
    Lu, S.
    Nadal, E.
    Ostoros, G.
    Felip, E.
    Spira, A. I.
    Lane, C. M.
    He, J.
    Chao, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1309 - S1310
  • [26] KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
    Bekaii-Saab, Tanios S.
    Spira, Alexander I.
    Yaeger, Rona
    Buchschacher, Gary L.
    McRee, Autumn Jackson
    Sabari, Joshua K.
    Johnson, Melissa Lynne
    Barve, Minal A.
    Hafez, Navid
    Velastegui, Karen
    Christensen, James G.
    Kheoh, Thian
    Der-Torossian, Hirak
    Rybkin, Igor I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
    Ernst, S. M.
    de Bruijn, P.
    van der Horst, T. E.
    Paats, M. S.
    Aerts, J. G.
    Mathijssen, R. H.
    Koolen, S. L.
    Dingemans, A-M. C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [28] WEE1 inhibition enhances anti-tumor activity of sotorasib in KRASG12C-mutated non-small cell lung cancer in preclinical models
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Yamauchi, Toyohiro
    Liu, Jie
    Ohashi, Akihiro
    Kobayashi, Susumu S.
    CANCER SCIENCE, 2023, 114 : 1043 - 1043
  • [29] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
    Johnson, M. L.
    Ou, S. H. I.
    Barve, M.
    Rybkin, I. I.
    Papadopoulos, K. P.
    Leal, T. A.
    Velastegui, K.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Weiss, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S2 - S2
  • [30] AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Uehara, Hisanori
    Takayama, Koichi
    CANCER RESEARCH, 2024, 84 (06)
12345